NIKKEI 225
38,946.93 -122.75 (-0.31%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
79.06 -0.74 (-0.93%) GOLD FUTURES
2,427.50 -11.00 (-0.45%) DOW
39,873.58 +66.81 (+0.17%) Bitcoin GBP
54,466.41 -874.25 (-1.58%)
STTK Sep 2024 12.500 call
| Previous close | 1.4500 |
| Open | 1.4500 |
| Bid | 0.8500 |
| Ask | 2.0000 |
| Strike | 12.50 |
| Expiry date | 2024-09-20 |
| Day's range | 1.4500 - 1.4500 |
| Contract range | N/A |
| Volume | |
| Open interest | 70 |
ZacksAfter Plunging -19.89% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK)
Shattuck Labs (STTK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
GlobeNewswireShattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress
– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients; successfully bridged responding TP53m AML patients to hematopoietic cell transplantation – – SL-172154 continued to demonstrate an acceptable safety profile in combination with AZA – – EHA poster presentation to include additional data from the next planned data cutoff in the second quarter of 2024 – AUSTIN, TX and DURHAM, NC, May 14, 2024 (GLOBE NEWS
ZacksWhat Makes Shattuck Labs (STTK) a New Buy Stock
Shattuck Labs (STTK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
